Kelly Chin, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Pulmonary and Critical Care Medicine

It's very rewarding as a physician to help patients improve with effective treatment options and impact their life in that way.

Dr. Chin holds a bachelor's degree with honors in biology from the University of Texas at Austin. She earned her medical degree and completed training in internal medicine at UT Southwestern Medical Center and completed a fellowship in pulmonary and critical care medicine at the University of California San Diego.  She also completed both a master's degree in clinical sciences  with honors from UTSW through the UT Southwestern Clinical Scholar's Program.  She is currently serving as Director, Pulmonary Hypertension Research and as the Medical Director for the Heart Lung Clinic at UT Southwestern.  She previously served as the Director of the UTSW Pulmonary Hypertension Program from 2010-2023.

Dr. Chin is board certified in pulmonary medicine and in critical care medicine.  Her clinical interests include pulmonary hypertension and chronic thromboembolic hypertension, and she has served as a principal investigator and as a steering committee member for multiple phase II, III and IV clinical trials in pulmonary hypertension.

Dr. Chin is listed in Texas Monthly's Super Doctor and D Magazine's Top Doctors 


Medical School
UT Southwestern Medical School (1996)
UT Southwestern Medical Center (2000), Internal Medicine
University of California at San Diego School of Medicine (2005), Pulmonary Diseases & Critical Care Medicine

Research Interest

  • Pulmonary Hypertension


Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset
Channick R, Chin KM, McLaughlin VV, Lammi MR, Zamanian RT, Turricchia S, Ong R, Mitchell L, Kim NH Cardiology and Therapy 2024 Jun 13 315-339
Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies
Kim NH, Chin KM, McLaughlin VV, DuBrock H, Restrepo-Jaramillo R, Safdar Z, MacDonald G, Martin N, Rosenberg D, Solonets M, Channick R Pulmonary Therapy 2024 Mar 10 85-107
Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)
McLaughlin V, Farber HW, Highland KB, Hemnes AR, Chakinala MM, Chin KM, Han M, Cho M, Tobore T, Rahman M, Kim NH Journal of Heart and Lung Transplantation 2024 Feb 43 272-283
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension
Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM Journal of the American College of Cardiology 2024 Jan 83 473-484
Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
Abu-Rmaileh M, Mirza O, Patel C, Shah T, Hardin EA, Bartolome SD, Chin KM Pulmonary Circulation 2023 Apr 13
Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?
Chin KM, Santiago-Munoz P Circulation 2023 Feb 147 562-564
Disentangling the Pulmonary Capillary Wedge Pressure from the Pulmonary Artery Pressure as the Hemodynamic Underpinning of Bendopnea
Thibodeau JT, Ravipati G, Pham DD, Ayers CR, Hardin EA, Chin KM, Grodin JL, Drazner MH Circulation: Heart Failure 2023 Feb 16 E010169
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
Gerry Coghlan J, Gaine S, Channick R, Chin KM, du Roure C, Gibbs JS, Hoeper MM, Lang IM, Mathai SC, McLaughlin VV, Mitchell L, Simonneau G, Sitbon O, Tapson VF, Galiè N ERJ Open Research 2023 Jan 9
Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension
Satish T, Chin K, Patel N Cardiology Research 2023 14 403-408
Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)
McLaughlin VV, Channick R, Kim NH, Frantz RP, McConnell JW, Melendres-Groves L, Miller C, Ravichandran A, Rodriguez-Lopez J, Brand M, Leroy S, Wetherill G, Chin KM Pulmonary Circulation 2022 Oct 12


Featured Books Legend Featured Books

Honors & Awards

  • Finalist, Alfred Soffer Research Award
    ACCP Original Research Award 2007
  • Southwestern Medical Foundation Medical School Scholarship
  • UT Southwestern Clinical Scholar, Class of 2011

Professional Associations/Affiliations

  • American College of Chest Physicians
  • American Medical Association
  • American Thoracic Society
  • Pulmonary Hypertension Association